The short version of reversed-phase HPLC fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-12-25. Anything still debated is marked as such rather than presented as settled.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
| Property | Value | Notes |
|---|---|---|
| Drug class | Peptide hormone analog | Acts at the growth hormone-releasing hormone receptor |
| Receptor | Growth hormone-releasing hormone receptor | G protein-coupled; raises cyclic AMP in somatotrophs |
| Key mediator | Insulin-like growth factor 1 | Increases with repeated administration |
| Main studied population | Adults with HIV-associated lipodystrophy | Trials measured visceral adipose tissue by imaging |
| Route | Subcutaneous injection | Given once daily in clinical use |
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Regulatory position depends on jurisdiction and on the form in which the material is sold. A branded product holds approval in the United States for a defined indication, and prescribing is confined to that label. Material marketed for laboratory research is not evaluated for human use and carries no such clearance. Independent verification therefore rests on certificates of analysis, third-party testing, and documented chain of custody. The substance also appears on the World Anti-Doping Agency prohibited list within the category covering growth hormone-releasing factors.
Lyophilized material is typically held under refrigeration between two and eight degrees Celsius, shielded from light and ambient moisture. Peptides of this size adsorb to glass and plastic, so working procedures often call for low-binding containers and as few transfers as possible. Absorbed water during weighing shifts the apparent mass of a sample, and controlling room humidity reduces that source of error. Once dissolved, solutions are kept cold and used within the interval printed on the accompanying label or certificate. Degradation accelerates markedly in dilute aqueous form.
Anti-nuclear protests first emerged in the late 1950s and early 1960s. In the United Kingdom, the first Aldermaston March, organised by the Campaign for Nuclear Disarmament, took place in 1958. In 1961, at the height of the Cold War, about 50,000 women brought together by Women Strike for Peace marched in 60 cities in the United States to demonstrate against nuclear weapons. In 1964, Peace Marches in several Australian capital cities featured "Ban the bomb" placards. In the early 1980s, the revival of the nuclear arms race triggered large protests about nuclear weapons. In October 1981 half a million people took to the streets in several cities in Italy, more than 250,000 people protested in Bonn, 250,000 demonstrated in London, and 100,000 marched in Brussels. The largest anti-nuclear protest was held on June 12, 1982, when one million people demonstrated in New York City against nuclear weapons. In October 1983, nearly 3 million people across western Europe protested nuclear missile deployments and demanded an end to the arms race; the largest crowd of almost one million people assembled in the Hague in the Netherlands. In Britain, 400,000 people participated in what was probably the largest demonstration in British history.
is a constant dependent on the boundary constraints of the structure. This is one of the main failure mechanisms for freeze casted materials. From this, the maximum compressive stress that an anisotropic porous solid can maintain is given by
=== New books === Titus Lewis & Joseph Harris (Gomer) - Y Drysorfa Efangylaidd William Richards - Address on the Duration or Perpetuity of Christian Baptism, with some Introductory Hints upon the Subjects and Mode of that Ordinance Thomas Roberts of Llwynrhudol - Amddiffyniad i'r Methodistiaid Charles Symmons - Life of Milton
==== Positive psychology interventions (PPI) in patients ==== A strengths-based approach to personal positive change aims to have clinical psychology place an equal weight on both positive and negative functioning when attempting to understand and treat distress. This rationale is based on empirical findings. Because positive characteristics interact with negative life events to predict disorder the exclusive study of negative life events could produce misleading results. Positive activity interventions, or PAIs, are brief self-administered exercises that promote positive feelings, thoughts, and behaviors. Two widely used PAIs are "Three Good Things" and "Best Future Self." "Three Good Things" requires a patient to daily document, for a week, three events that went well during the day, and the respective cause, or causes (this exercise can be modified with counterfactual thinking, that is, adding the imagination of things had them been worse). "Best Future Self" has a patient "think about their life in the future, and imagine that everything has gone as well as it possibly could. They have worked hard and succeeded at accomplishing all of their life goals. Think of this as the realization of all of their life dreams." The patient is then asked to write down what they imagined. These positive interventions have been shown to decrease depression, and interventions focusing on strengths and positive emotions can, in fact, be as effective in treating disorder as other more commonly used approaches such as cognitive behavioral therapy.
Sources: en.wikipedia.org
In 2008, Guinness World Records awarded Half-Life 2 the records for "Highest-rated Shooter by PC Gamer" and "First game to feature a gravity gun". In 2009, Game Informer named Half-Life 2 the fifth-best game, writing that "Valve redefined the way first-person shooters were created". Half-Life 2 was selected by readers of The Guardian as the best game of the decade, with particular praise for the environment design. The Guardian journalist Keith Stuart wrote that it "pushed the envelope for the genre, and set a new high watermark for FPS narrative". Half-Life 2 won Crispy Gamer's Game of the Decade tournament style poll. It also won Reviews on the Run's, IGN's Best Game of the Decade and Spike Video Game Awards 2012 Game of the Decade. In December 2021, IGN named Half-Life 2 the ninth-best game of all time.
Valproic acid has a black box warning for hepatotoxicity, pancreatitis, and fetal abnormalities. There is evidence that valproic acid may cause premature growth plate ossification in children and adolescents, resulting in decreased height. Valproic acid can also cause mydriasis, a dilation of the pupils. There is evidence that shows valproic acid may increase the chance of Polyendocrine metabolic ovarian syndrome (PMOS) in women with epilepsy or bipolar disorder. Studies have shown this risk of PMOS is higher in women with epilepsy compared to those with bipolar disorder. Weight gain is also possible. Valproic acid may decrease platelets in proportion to its dosage, particularly in women and the elderly.
For example, human height is a trait with complex causes. It has a heritability of 89% in the United States. In Nigeria, however, where people experience a more variable access to good nutrition and health care, height has a heritability of only 62%.
=== 1990s === 1994: divests its Waters Chromatography Division to focus on its membrane business 1996: acquires Amicon separation sciences business from W. R. Grace and Company 1997: acquires Tylan General, expanding its gas purification offerings for the microelectronics industry 1999: acquires Bioprocessing Limited, a developer and manufacturer of chromatography
== Working == A basic TDLAS setup consists of a tunable diode laser light source, transmitting (i.e. beam shaping) optics, optically accessible absorbing medium, receiving optics and detector/s. The emission wavelength of the tunable diode laser, viz. VCSEL, DFB, etc., is tuned over the characteristic absorption lines of a species in the gas in the path of the laser beam. This causes a reduction of the measured signal intensity due to absorption, which can be detected by a photodiode, and then used to determine the gas concentration and other properties as described later. Different diode lasers are used based on the application and the range over which tuning is to be performed. Typical examples are InGaAsP/InP (tunable over 900 nm to 1.6 μm), InGaAsP/InAsP (tunable over 1.6 μm to 2.2 μm), etc. These lasers can be tuned by either adjusting their temperature or by changing injection current density into the gain medium. While temperature changes allow tuning over 100 cm−1, it is limited by slow tuning rates (a few hertz), due to the thermal inertia of the system. On the other hand, adjusting the injection current can provide tuning at rates as high as ~10 GHz, but it is restricted to a smaller range (about 1 to 2 cm−1) over which the tuning can be performed. The typical laser linewidth is of the order of 10−3 cm−1 or smaller. Additional tuning, and linewidth narrowing, methods include the use of extracavity dispersive optics.
Sources: en.wikipedia.org
== Clinical studies == Randomized trials have evaluated Dexcom systems as part of real-time CGM-based diabetes management. In the 2020 MILLENNIALS crossover trial, participants aged 16–24 years with type 1 diabetes used the Dexcom G6 for eight weeks and conventional self-monitoring of blood glucose for eight weeks. During G6 use, the mean percentage of time in the target glucose range of 70–180 mg/dL was 35.7%, compared with 24.6% during self-monitoring, and mean glycated hemoglobin (HbA1c) was 0.76 percentage points lower. The 2021 MOBILE trial randomly assigned 175 adults with poorly controlled type 2 diabetes, treated with basal insulin but not mealtime insulin, to use either the G6 or a conventional blood glucose meter for eight months. HbA1c decreased by 1.1 percentage points in the G6 group and by 0.6 points in the meter group; after adjustment, the between-group difference was 0.4 percentage points. Mean time in the 70–180 mg/dL range was 59% with the G6 and 43% with meter monitoring, while one participant in each group experienced severe hypoglycemia. The study and devices were funded by Dexcom, and a Dexcom employee was among the authors. Both trials compared a CGM-enabled management strategy with fingerstick-based monitoring; they did not compare the G6 with another CGM system.
As filaments grow, the pool of available G-actin molecules is managed by G-actin-binding proteins such as profilin and thymosin β-4. Profilin ensures a supply of available actin-ATP by binding to ADP-bound G-actin and promoting the exchange of ADP for ATP. Profilin's binding to the actin molecule physically blocks its addition to a filament's (−) end, but permits it to join the (+) end. Once the actin-ATP has joined the filament, profilin releases it. As formins promote the nucleation and extension of new actin filaments, they recruit profilin to the area, increasing the local concentration of actin-ATP to boost filament growth. In contrast, thymosin β-4 binds and sequesters actin-ATP, preventing it from joining a microfilament. Once an actin fiber is established, the dynamics of its growth or collapse are influenced by numerous proteins. Existing strands can be interrupted by filament cleaving proteins, such as cofilin and gelsolin. Cofilin binds along two actin-ADP molecules in a filament, forcing a movement that destabilizes the filament and causes it to break. Gelsolin inserts itself between actin molecules in a filament, disrupting the filament. After the filament breaks, gelsolin remains attached to the new (+) end, preventing it from growing, thus forcing its disassembly.
=== Hair loss === Minoxidil is used for the treatment of hair loss. It is mainly used topically, but in more recent years, it also being used at low doses orally and to a lesser extent sublingually. The drug is effective in helping promote hair growth in both men and women with androgenic alopecia (androgen-dependent pattern hair loss). It works by increasing hair counts as well as by thickening individual hair follicles. Minoxidil is less effective when the area of hair loss is large. In addition, its effectiveness has largely been demonstrated in younger men who have experienced hair loss for less than 5 years. Minoxidil use is indicated for central (vertex) hair loss only. Minoxidil must be used indefinitely for continued support of existing hair follicles and the maintenance of any experienced hair regrowth. Its benefits are tangible but fully reversible, with discontinuation following long-term treatment resulting in rapid hair loss and similar hair density as placebo at 24 weeks post-discontinuation. As such, minoxidil does not appear to prevent hair loss long term. Low-dose oral minoxidil (LDOM) is used off-label against hair loss and to promote hair regrowth. Oral minoxidil is an effective and well-tolerated treatment alternative for patients having difficulty with topical formulations. It is notable in this regard that topical minoxidil for hair loss has very low compliance rates, with almost all users discontinuing it after 1 year of use. Consensus statements provide guidance on use of low-dose oral minoxidil for hair loss.
=== Slovak === Traditionally, the word najneobhospodarovávateľnejšieho ("of the least cultivable", 31 letters) is considered as the longest Slovak word, but there are some longer artificial words. Most of them are compound adjectives in dative, instrumental or other grammatical case and derived from the iterative or frequentative verbal form or the ability adjective form (like -able).
Schleswig-Holstein has an aging population. Since 1972, there has been a decrease in the natural rate of population change. In 2016, the total fertility rate reached 1.61, the highest value in 40 years (the average value being 1.4). In 2016, there were 25,420 births and 33,879 deaths, resulting in a natural decrease of −8,459.
Sources: en.wikipedia.org
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.
Administered growth hormone supplies the hormone directly, while this peptide acts upstream by prompting the pituitary to release it. The indirect route preserves pulsatile secretion and some endogenous feedback, which changes the hormone and IGF-1 profile observed after treatment.
Reductions in visceral adipose tissue appear consistently in randomized trials of the approved population. Effects on peripheral fat, cardiovascular outcomes, and use outside that population are less well established.
It acts on the growth hormone–releasing hormone receptor, a Gs-coupled receptor found on pituitary somatotroph cells. Activation raises cAMP and prompts pulsatile hormone release.